Search results for "cd34"

showing 10 items of 148 documents

Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results…

2015

Beyond hemoglobin (Hb) levels and performance status, further surrogate markers of appropriate transfusion management should improve the quality of thalassemia care. We investigated the levels of peripheral circulating CD34+ stem cells as an independent marker of appropriate hematopoietic balance in patients with thalassemia.Peripheral circulating CD34+ stem cells, colony-forming unitgranulocyte, erythrocyte, macrophage, magakaryocyte (CF-GEMM), colony-forming unitgranulocyte/macrophage (CFU-GM), and erythroidburst-forming units (BFU-E) were assayed, according to standard procedures. Patients with thalassemia major (TM) and thalassemia intermedia (TI) were tested and compared to healthy con…

AdultMaleAdolescentbeta-ThalassemiaHematopoietic Stem Cell TransplantationPilot ProjectsMiddle AgedHematopoietic Stem CellsPrognosisSettore MED/15 - Malattie Del SangueYoung AdultPeripheral CD34+ stem cells beta-thalassemiaTreatment OutcomeCase-Control StudiesHumansFemaleBiomarkersAgedFollow-Up Studies
researchProduct

D2-40 negative pyogenic granuloma-like Kaposi's sarcoma: Diagnostic features and histogenetic hypothesis of an uncommon skin tumor in HIV-negative pa…

2015

Locate full-text(opens in a new window)|View at Publisher| Export | Download | Add to List | More... Pathology Research and Practice Volume 211, Issue 7, July 01, 2015, Pages 528-532 D2-40 negative pyogenic granuloma-like Kaposi's sarcoma: Diagnostic features and histogenetic hypothesis of an uncommon skin tumor in HIV-negative patients (Article) Cabibi, D.a, Giannone, A.G.a , Guarnotta, C.a, Schillaci, O.b, Franco, V.a a Department of Sciences for Promotion of Health and Mother and Child Care, University of Palermo, Palermo, Italy b Servizio di Anatomia Patologica, Dipartimento Oncologico di III livello, La Maddalena Casa di Cura di Alta Specialità, Palermo, Italy View references (20) Abst…

AdultMaleCD31Pathologymedicine.medical_specialtySkin NeoplasmsCD34Pyogenic granuloma-like Kaposi's sarcomaSettore MED/08 - Anatomia PatologicaVascular tumorPathology and Forensic MedicineD2-40Antibodies Monoclonal Murine-DerivedBiomarkers TumormedicineHHV8HumansGranuloma PyogenicSarcoma KaposiKaposi's sarcomaSkinRetrospective StudiesPodoplaninPyogenic granulomabusiness.industryKaposi's sarcomaCell BiologyMiddle Agedmedicine.diseaseImmunohistochemistryPyogenic granulomaLymphatic systemHerpesvirus 8 HumanFemaleSarcomaDifferential diagnosisbusinessImmunostainingPathology - Research and Practice
researchProduct

Molecular diagnosis of dermatofibrosarcoma protuberans: A comparison between reverse transcriptase-polymerase chain reaction and fluorescence in situ…

2011

Dermatofibrosarcoma protuberans (DFSP) is characterized by the presence of the t(17;22)(q22;q13) that leads to the fusion of the COL1A1 and PDGFB genes. This translocation can be detected by multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) or fluorescence in situ hybridization (FISH) techniques. We have evaluated the usefulness of a dual color dual fusion FISH probe strategy for COL1A1/PDGFB detection in a series of 103 archival DFSPs and compared the obtained results with RT-PCR analyses. FISH and RT-PCR were carried out on paraffin embedded tissue samples. Regarding the RT-PCR approach, all COL1A1 exons and exon 2 of PDGFB were evaluated. Sensitivity, specificity, positi…

AdultMaleCancer ResearchCD34Chromosomal translocationBiologyCollagen Type Ilaw.inventionlawGeneticsmedicineDermatofibrosarcoma protuberansHumansChildIn Situ Hybridization FluorescencePolymerase chain reactionFibrosarcomatous Dermatofibrosarcoma ProtuberansPDGFBmedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionDermatofibrosarcomaProto-Oncogene Proteins c-sismedicine.diseaseMolecular biologyCollagen Type I alpha 1 ChainImmunohistochemistryFluorescence in situ hybridizationGenes Chromosomes and Cancer
researchProduct

Poorly differentiated synovial sarcoma: A case report

2001

Poorly differentiated synovial sarcoma is a rare soft tissue tumor. We studied a case arising in the pleural cavity of a young subject, characterised by the presence of spindle cell, small cell, and large epithelioid cell areas. We performed stains for mucosubstances and analysed the expression of cytokeratins 5/6, 7, 8, 18, 19, CEA, CD34, Ber-Ep4 and calretinin to characterize the phenotype of this neoplasm. We furthermore assessed immunohistochemically the presence of p53, Bcl-2, Bax and caspase 3, four apoptotic markers, to evaluate a relationship between apoptotic activity and the behaviour of this tumor. Our findings showed a strong presence of calretinin, p53 and Bcl-2 in all three ar…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyPleural Neoplasms2734CD34Caspase 3Pathology and Forensic MedicineSynovial sarcomaImmunoenzyme TechniquesSarcoma SynovialS100 Calcium Binding Protein GBcl-2-associated X proteinCalretininProto-Oncogene ProteinsBiomarkers TumormedicineHumansCaspasebcl-2-Associated X ProteinbiologyCaspase 3ApoptosiSoft tissue tumorGeneral MedicinePoorly differentiated synovial sarcomamedicine.diseaseSynovial sarcomaNeoplasm ProteinsApoptosis; Calretinin; Poorly differentiated synovial sarcoma; Soft tissue tumors; Synovial sarcoma; Cancer Research; Oncology; 2734Proto-Oncogene Proteins c-bcl-2OncologyCalbindin 2Caspasesbiology.proteinSarcomaTumor Suppressor Protein p53CalretininEpithelioid cell
researchProduct

CONSISTENT BONE MARROW-DERIVED CELL MOBILIZATION FOLLOWING REPEATED SHORT COURSES OF GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH AMYOTROPH…

2009

Background and aims. The aim of this study was to evaluate and characterize the feasibility and safety of bone marrow-derived cell (BMC) mobilization following repeated courses of granulocyte-colony stimulating factor (G-CSF) in patients with amyotrophic lateral sclerosis (ALS). Methods. Between January 2006 and March 2007, 26 ALS patients entered a multicenter trial that included four courses of BMC mobilization at 3-month intervals. In each course, G-CSF (5 mu g/kg b.i.d.) was administered for four consecutive days; 18% mannitol was also given. Mobilization was monitored by flow cytometry analysis of circulating CD34(+) cells and by in vitro colony assay for clonogenic progenitors. Co-exp…

AdultMaleCancer Researchmedicine.medical_specialtySLa - trial clinico - C-GSFImmunologyAntigens CD34Bone Marrow CellsDrug Administration ScheduleColony-Forming Units AssayCell MovementInternal medicineMulticenter trialmedicineImmunology and AllergyHumansCell LineageProspective StudiesAmyotrophic lateral sclerosisProspective cohort studyGenetics (clinical)Hematopoietic Stem Cell MobilizationNeuronsTransplantationMobilizationbusiness.industryStem CellsAmyotrophic Lateral SclerosisGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationCell BiologyMiddle Agedmedicine.diseaseHematopoietic Stem CellsBone Marrow-Derived CellHematopoietic Stem Cell MobilizationSurgeryGranulocyte colony-stimulating factorNerve RegenerationSettore MED/26 - NEUROLOGIAGranulocyte macrophage colony-stimulating factorTreatment OutcomeOncologyBiological MarkersFemalebusinessNeurogliaBiomarkersmedicine.drug
researchProduct

Successful treatment of resistant thrombotic thrombocytopenic purpura/hemolytic uremic syndrome with autologous peripheral blood stem and progenitor …

1999

The first-line treatment of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS syndrome) induces a response and survival rate of approximately 85%, even if a considerable number of patients relapse; nevertheless, a number of these patients are resistant to conventional management. Immunoablation followed by stem cell transplantation has been shown to be capable of inducing remissions in a large spectrum of experimental autoimmune disorders. We report here the case of a 20-year-old male patient with the TTP-HUS syndrome who was resistant to conventional treatment and was transplanted with autologous immunoselected CD34+ PBPC after conditioning with cyclosphosphamide, anti…

AdultMaleHemolytic anemiaLymphocyteThrombotic thrombocytopenic purpuraAntigens CD34Transplantation AutologousPrednisonehemic and lymphatic diseasesHumansMedicineProgenitor cellSurvival rateTransplantationPurpura Thrombotic Thrombocytopenicbusiness.industryHematopoietic Stem Cell TransplantationHematologyHematopoietic Stem Cellsmedicine.diseaseTransplantationmedicine.anatomical_structureHemolytic-Uremic SyndromeImmunologyStem cellbusinessmedicine.drugBone Marrow Transplantation
researchProduct

Primordial odontogenic tumor : a systematic review

2019

Background The primordial odontogenic tumor (POT) is a recently described benign entity with histopathological and immunohistochemical features suggesting its origin during early odontogenesis. Aim: To integrate the available data published on POT into a comprehensive analysis to better define its clinicopathological and molecular features. Material and Methods An electronic systematic review was performed up to September 2019 in multiple databases. Results A total of 13 publications were included, representing 16 reported cases and 3 molecular studies. The mean age of the affected patients was 11.6 years (range 2-19), with a slight predominance in males (56.25%). The posterior mandible was…

AdultMalePathologymedicine.medical_specialtyAdolescentCD34VimentinOdontogenic TumorsMandibleReviewEpitheliumLesionVariable Expression03 medical and health sciencesYoung Adult0302 clinical medicineSurvivinmedicineHumansPrimordial odontogenic tumorChildGeneral DentistryOral Medicine and Pathologybiologybusiness.industryOdontogenic tumor030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseasestomatognathic diseasesOtorhinolaryngologyChild PreschoolUNESCO::CIENCIAS MÉDICASbiology.proteinSystematic reviewImmunohistochemistryOdontogenesisSurgerymedicine.symptomAmelogeninNeoplasm Recurrence Localbusiness
researchProduct

Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients

2015

Melanomas are aggressive skin tumors characterized by high metastatic potential. Our previous results indicate that Natural Killer (NK) cells may control growth of melanoma. The main defect of blood NK cells was a decreased expression of activating NCR1/NKp46 receptor and a positive correlation of NKp46 expression with disease outcome in stage IV melanoma patients was found. In addition, in stage III melanoma patients, we identified a new subset of mature NK cells in macro-metastatic Lymph nodes (LN). In the present studies, we evaluated the numbers of NK cells infiltrating primary cutaneous melanoma and analyzed immune cell subsets in a series of sentinel lymph nodes (SLN). First, we show …

AdultMalePathologymedicine.medical_specialtyCD34lcsh:MedicineCD8-Positive T-LymphocytesBiologyTumor MicroenvironmentmedicineHumansCytotoxic T celllcsh:ScienceMelanomaAgedNeoplasm StagingAged 80 and overTumor microenvironmentMultidisciplinarySentinel Lymph Node BiopsyMacrophagesMelanomalcsh:REndothelial CellsMiddle Agedmedicine.diseaseAntigens Differentiation3. Good healthKiller Cells NaturalGranzyme BCutaneous melanomalcsh:QFemaleLymphCD8Research ArticlePLOS ONE
researchProduct

Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications.

2009

Aims:  To analyse the presence of collagen type I alpha 1–platelet-derived growth factor beta (COL1A1–PDGFB) transcripts in 20 cases of dermatofibrosarcoma protuberans (DFSP) and to assess the relationship between COL1A1 breakpoints and clinical and histopathological variables. Methods and results:  Multiplex reverse transcriptase-polymerase chain reaction was carried out using frozen tissue. Our series contained 14 men and six women. Histologically, most cases were of conventional type (n = 9), followed by fibrosarcoma (n = 4), Bednar tumour (n = 2), sclerosing (n = 2), myoid (n = 1) and atrophic (n = 1) DFSP, and giant cell fibroblastoma (n = 1). Immunohistochemistry revealed CD34 express…

AdultMalePathologymedicine.medical_specialtyHistologySkin NeoplasmsAdolescentCD34Antineoplastic AgentsBiologyCollagen Type IPiperazinesPathology and Forensic MedicineYoung AdultDermatofibrosarcoma protuberansmedicineHumansAgedDNA PrimersAged 80 and overPDGFBBase SequenceDermatofibrosarcomaGeneral MedicineGiant-cell fibroblastomaMiddle Agedmedicine.diseaseMohs SurgeryCollagen Type I alpha 1 ChainImatinib mesylatePyrimidinesFusion transcriptCOL1A1/PDGFB Fusion GeneBenzamidesImatinib MesylateFemaleGene FusionDermatofibrosarcomaGenes sisHistopathology
researchProduct

Intravascular papillary endothelial hyperplasia: report of 4 cases with immunohistochemical findings.

2008

Intravascular papillary endothelial hyperplasia (IPEH) is a benign endothelial proliferation, usually intravascular, that may mimic angiosarcoma. In this report, four new cases of IPEH involving the oral region are described. The affected sites were the lower lip, labial comissure and the submandibular region. After clinical evaluation, the complete removal of the lesions showed a circumscribed and soft mass. Histologically, the major feature was a reactive proliferation of endothelial cells composed of small papillary structures with hypocellular and hyalinized cores arising in an organized thrombus. Immunohistochemical staining for CD34 was strongly positive in endothelial cells. Vimentin…

AdultMalePathologymedicine.medical_specialtyProliferative indexEndotheliumCD34VimentinmedicineHumansAngiosarcomaGeneral DentistryAgedHyperplasiabiologybusiness.industryHyperplasiaMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseImmunohistochemistrymedicine.anatomical_structureOtorhinolaryngologyIntravascular papillary endothelial hyperplasiaUNESCO::CIENCIAS MÉDICASbiology.proteinImmunohistochemistrySurgeryFemaleEndothelium VascularbusinessMouth DiseasesMedicina oral, patologia oral y cirugia bucal
researchProduct